GrowLife, Inc. Announces Renowned Additions to Advisory Board Focused on Expanding CBD Hemp Starter Business

KIRKLAND, Wash., July 21, 2020 (GLOBE NEWSWIRE) — GrowLife, Inc. (OTCQB: PHOT) (“GrowLife” or the “Company”), one of the nation’s most recognized indoor cultivation product and service providers, today announced two additions to the company’s advisory board, Mr. Lewis Swarts and Dr. Daniel Harder. Each brings unique experience that will assist the company in expanding its CBD-rich hemp cloning business.

“We could not have asked for two better additions to our advisory board than Mr. Swarts and Dr. Harder” said Marco Hegyi, CEO of GrowLife. “Looking at their rich backgrounds, they are adding world-class experience in hemp cultivation operations, enabling us to better serve the supply chain and address the challenges hemp farmers are facing, paired with a scientific outlook rarely seen in the cannabis space. We have always prided ourselves in working with the best, now adding these two experts to our advisory board elevates GrowLife’s position even further as true leaders of innovation within the cloning industry. We continue to see strong demand for CBD consumer products and providing the raw-material infrastructure necessary to meet this demand is exactly where GrowLife will continue to capitalize.”

Mr. Swarts is a cannabis industry veteran, having worked in executive positions at some of the world’s largest cannabis and agriculture companies for more than ten years. He brings unparalleled experience in managing operational efficiencies for large-scale cannabis and hemp cultivation organizations. This experience adds immense value to GrowLife’s expanding CBD-rich hemp clone operation. Mr. Swarts’ previous titles include Managing Director and Vice-President of Operations at cannabis and hemp production facilities as well as currently holding a senior leadership position at one of the largest vertically-integrated hemp manufacturers in the US. Mr. Swarts joins the advisory board with a passion for and an understanding of the potential of CBD-rich hemp and will focus on streamlining and expanding that part of GrowLife’s business.

Dr. Harder is a plant scientist who has dedicated his career to Botany and Agronomic Genomics. A graduate of University of California, Berkeley, Dr. Harder has held multiple professional, legislative and board positions at highly respected plant science foundations, gardens, and academic organizations. He is a multi-published author on the topics of botany and identification and verification of plant species and environmental considerations. As an advisory board member, Dr. Harder will work with members of GrowLife team to expand their knowledge of plant genetics and work to bring even greater quality to GrowLife’s hemp clone products.

“I am honored and excited by the opportunity to join GrowLife’s advisory board” said Lewis Swarts. “The company is well positioned to be the leader in not only cloning equipment, but CBD-rich hemp starters nationwide. Cloning is the preferred way for many farmers to guarantee the CBD potency of their hemp plants and I plan to use my experience in hemp cultivation operations to further GrowLife’s reach in this expanding industry.”

“As a lifetime plant researcher, I am eager to help GrowLife’s team further their genetics expertise on plant cultivation” added Dr. Daniel Harder. “I have assisted countless farmers in understanding their crops, for their region and environmental conditions, and I hope to pass this understanding onto the GrowLife team so that they may be able to best serve their customers to grow superior performing CBD-rich hemp through use of the company’s proprietary starters.”

About GrowLife, Inc.

GrowLife, Inc. (PHOT) aims to become the nation’s largest cultivation service provider for cultivating organics, herbs and greens and plant-based medicines. Our mission is to help make our customers successful. Through a network of local representatives covering the United States and Canada, regional centers and its e-Commerce team, GrowLife provides essential goods and services including media, industry-leading hydroponics and soil, plant nutrients, and thousands of more products to specialty grow operations. GrowLife is headquartered in Kirkland, Washington and was founded in 2012.

Public Relations Contact:

CMW Media
Cassandra Dowell, 858-264-6600
cassandra@cmwmedia.com
www.cmwmedia.com

Investor Relations Contact:
investors@growlifeinc.com
206-483-0059

FORWARD LOOKING STATEMENT:

This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of GrowLife, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words may, would, will, expect, estimate, can, believe, potential and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond GrowLife, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

COVID-19 Database of Worldwide Travel Guidelines Now Available To All trivago Travelers

As some regions of the world begin to relax travel restrictions while others impose new quarantines, trivago N.V. (NASDAQ: TRVG) announced the launch of its new COVID-19 database is now available for travelers.  The database  aggregates the most updated information on restrictions for travelers into a single, consolidated source.

Travelers and businesses can now access the free database for up-to-date details including any restrictions on entry, social distancing rules, the use of personal protective equipment in accommodations, and open activities and businesses at the destination. Users simply select the country and region they are looking to visit, and the platform returns details on whether the location is open for domestic and/or international travel and the length of quarantine restrictions, if any. The resulting information also includes the status for hotels, vacation rentals, restaurants, bars, night clubs, museums and other events at the location. When travelers look to book accommodations on the trivago website, they will see a banner at the top of the page linking them to the COVID database.  For example, www.trivago.de/corona or www.trivago.com/corona

“Due to the massive challenges brought on by the global pandemic, today’s travelers face several important questions before booking vacations, especially as restrictions vary widely depending on jurisdiction. This database provides the transparency and detailed information they need in one place, without having to search through numerous websites and other sources in order to make their travel decisions,” explained Axel Hefer, CEO trivago.

The European COVID-19 Travel Alliance, which includes trivago, gathers the source materials for the database from reputable government sources for each country and region. This initiative supports local tourism industries, providing a resource for travelers and travel institutions to pass along the information to their customers online and through mobile applications.

Please note the content on this website is not exhaustive and is solely provided to assist visitors of this website at this time of disruption on an “AS IS” basis. Information is subject to change without prior notice and at the sole discretion of the subject contributors to this website. Given the rapidly evolving nature of the COVID-19 situation and the contributors to this website’s response to it, we cannot guarantee the accuracy of the information in these sites and cannot accept any liability for any errors or omissions nor can you, in your capacity as a visitor of this website, derive any rights from it.

About trivago
trivago is a leading global hotel search platform focused on reshaping the way travelers search for and compare hotels and alternative accommodations. Incorporated in 2005 in Düsseldorf, Germany, the platform allows travelers to make informed decisions by personalizing their hotel search and providing them access to a deep supply of hotel information and prices. trivago enables its advertisers to grow their businesses by providing access to a broad audience of travelers via its websites and apps. As of March 31, 2020, trivago has established 54 localized platforms connected to over 4.5 million hotels and alternative accommodations, in over 190 countries.

Forward looking statements
This press release contains certain forward-looking statements. Words, and variations of words such as “believe,” “expect,” “plan,” “continue,” “will,” “should,” and similar expressions are intended to identify our forward-looking statements. These forward-looking statements involve risks and uncertainties, many of which are beyond our control, and important factors that could cause actual events and results to differ materially from those in the forward-looking statements. For additional information factors that could affect our forward-looking statements, see our risk factors, as they may be amended from time to time, set forth in our public filings with the Securities and Exchange Commission. We disclaim and do not undertake any obligation to update or revise any forward-looking statement in this press release, except as required by applicable law or regulation.

Media Contact:
Stephanie Lowenthal
stephanie.lowenthal@trivago.com

Interferon Treatment Trial ‘a Major Breakthrough’ Against the Covid-19 Pandemic

NEW YORK CITY, July 21, 2020 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (OTCQB:BETRD) (CSE:BETR) has been a strong advocate and defender of using interferons as treatment for COVID-19, in particular as delivered through an inhalation device.

Now, the preliminary results of a clinical trial by a UK biotech have confirmed the premise advocated by the Company, suggesting that an interferon inhalation treatment for COVID-19 reduces the number of patients needing intensive care.

In the UK study, the treatment was delivered through a nebulizer and inhaled directly into the lungs of patients with coronavirus. The initial findings suggest the treatment cut the odds of a COVID-19 patient in hospital developing severe disease – such as requiring ventilation – by 79%.

The study reported “very significant” reductions in breathlessness among patients who received the treatment and highlighted how patients were two to three times more likely to recover to the point where everyday activities were not compromised by their illness, according to the study claims.

In addition, the average time patients spent in hospital is said to have been reduced by a third, for those receiving the new drug – down from an average of nine days to six days.

The treatment in the study used interferon beta, as opposed to the patent-pending interferon alpha 2b (IFN-a2b) treatment developed by BetterLife called AP-003.

Whether alpha or beta, both interferon proteins are produced when the body encounters a viral infection and act as antiviral agents, modulating functions of the immune system.  Interferons were so named for their ability to “interfere” with viral replication by protecting cells from virus infections.

IFN-a2b has been used with great success with other respiratory illnesses. Interferon treatments have been studied against coronaviruses including MERS-CoV, SARS-Cov-1 and now SARS-CoV-2 (the causative agent of COVID-19).

Of the three coronaviruses which cause severe human disease, SARS-CoV-2 displays substantial sensitivity to interferon alpha. Studies in COVID-19 patients show that IFN-a2b inhalation reduces the infection rate of SARS-CoV-2.

BetterLife is planning to initiate its Phase II study later this summer with its proprietary IFN-a2b formula called AP-003.  AP-003 is a patent pending isoform-free form of interferon alpha 2b. This means that as a purer form of interferon it is potentially less toxic, clearing the way for higher doses to be administered.

BetterLife hope that an inhaler, similar to one used in the UK study, will deliver AP-003 directly to a patient’s lungs in the hope of stimulating immune response. The treatment is aimed at preventing infected patients deteriorating from requiring oxygen to being placed on a ventilator, as suggested by the findings of the UK study.

The company is also aiming to develop a low dose version of AP-003 that may serve as a prophylaxis or prevention treatment for front-line workers and those at high risk for COVID-19 infections.

In discussing the news with BDA, Ahmad Doroudian, Chief Executive Officer of BetterLife commented “We are encouraged by the positive results from this trial as it further confirms the proof of concept of anti-COVID treatment via IFN inhalation. We look forward to our proposed 150 patient clinical trials using AP-003 (inhaled IFN alpha 2b) in COVID-19 patients.

BetterLife’s team believes that the isoform-free IFN alpha2b will provide a potentially superior treatment regimen for Covid-19 patients, as IFN-a2b has already been used to successfully treat other viral infections such as HCV and HBV.

To learn more about AP-003 please visit www.BlifeTherapeutics.com

Note:

BetterLife Pharma has not made any express or implied claims that AP-003 or any other product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. Further, the safety and efficacy of AP-003 are under investigation and market authorization has not yet been obtained.

Disclosure: BetterLife Pharma is a client of BDA International.

About BDA International, Inc.:

BDA International is an independent global firm offering a wide range of IR and PR related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles hold shares of client companies in our personal portfolios, including BETRF. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and BETRF may do so via the contact information at the bottom of this release.

Disclaimer

The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. BetterLife Pharma is a client of BDA International. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.

Investor Relations Contact:
Dost Mushtaq
BDA International    
www.bda-ir.com
dost@bda-ir.com

MediPharm Labs to Present at the Avicanna Hosted Virtual Symposium Titled “Medical Cannabis 2.0” in Partnership with Medical Cannabis by Shoppers™

• This year’s annual symposium coincides with the expected launch of Avicanna Inc’s (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) RHO Phyto™ advanced medical cannabis products, manufactured by MediPharm Labs.

• In the wake of COVID-19, a virtual format will be used that allows for a broader reach to global patients and the medical community.

• The symposium will present the evolution of medical cannabis including the Avicanna-led advancements, in collaboration with MediPharm Labs for R&D for novel cannabinoid delivery forms and formulations in addition to enhanced access for patients by Medical Cannabis by Shoppers.

• Leading experts in R&D and clinical development will discuss the potential therapeutic benefits of medical cannabis to address the importance of working with healthcare practitioners for safe and effective dosing.

BARRIE, Ontario, July 21, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that Pat McCutcheon, CEO & Co-Founder of MediPharm Labs will be participating at the Avicanna Hosted Virtual Symposium Titled “Medical Cannabis 2.0“ in Partnership with Medical Cannabis By Shoppers™.

Patients and health care practitioners globally can join the virtual symposium to learn more about the potential advantages of medical cannabis and the advancement of product offerings including MediPharm Labs manufactured products such as Avicanna’ s RHO Phyto™ product offerings. In addition, experts will discuss the pharmacology, safety, and dosing guidelines of medical cannabis for therapeutic conditions. This includes presentations on the, efficacy of cannabinoids for chronic pain, anxiety, depression, and comorbidities as well as an overview of the patient pathway to Medical Cannabis by Shoppers.

The webcast presentation will begin at 10:00am Eastern Time, and Pat McCutcheon, CEO of MediPharm Labs will be presenting on a panel at 12:50pm Eastern Time. Participants may view the full agenda and access the webcast using the following link: https://www.avicanna.com/symposium/ or through the events section of MediPharm Labs Investor Relations website at https://ir.medipharmlabs.com/ir-calendar.

About MediPharm Labs

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing commercialization of its Australian extraction facility. MediPharm Labs Australia was established in 2017.

For further information, please contact:
Laura Lepore, VP, Investor Relations and Communications
Telephone: 416-913-7425 ext. 1525
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

Rapid Dose Therapeutics and McMaster University Initiate QuickStrip™ COVID-19 Vaccine Research With Immediate Impact

BURLINGTON, Ontario, July 21, 2020 (GLOBE NEWSWIRE) — Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian Life Sciences company focused on innovative drug and active ingredient delivery solutions, is pleased to announce it has begun COVID-19 vaccine research in conjunction with McMaster University and the team lead by Drs. Alex Adronov, James Mahony, and Mark Larché. The federally-funded project tests the use of QuickStrip™ for administering vaccines orally as a convenient and safe alternative to injection with needles, the currently accepted delivery format for most vaccines.

Dr. Adronov is a recognized Canadian expert in synthetic polymer chemistry and the development of novel polymer architectures, Dr. Mahony has extensive experience in virology and vaccine development, and Dr. Larché is an immunologist with expertise in vaccine research geared toward treatment of common allergies. The combined expertise of this research team will enable development and evaluation of oral vaccine delivery strategies.

Jason Lewis, RDT SVP said “RDT is focused on novel research through collaboration with the experts at McMaster. We see QuickStrip™, oral mucosa thin film delivery, as an efficient solution for distributing vaccines globally. Experts believe that antigens to COVID and other viruses can be delivered sublingually, a much easier and less expensive process than the current single or multidose vial methods.  Imagine the significance of creating a vaccine that can be sent in an envelope, by mail.”

“Our combined experience indicates that this is very feasible” said Dr. Adronov a recognized polymer expert leading the research project. “Our past collaborations with RDT in developing polymeric delivery innovations have resulted in solutions we are proud of, and continue to be involved with. Globally, we are seeing the development of many vaccines that we believe can be applied using sublingual delivery. Our project focuses on producing a polymer strip that delivers viral antigens by a transmucosal approach rather than injection. This funding will allow us to quickly get started, and we expect to generate positive results in the near future.”

Mark Upsdell, RDT CEO, said “The current COVID situation requires everyone to think outside of the box as to how we might deliver safe, effective and timely solutions for combating COVID-19 and other viruses that require serum-based defenses. RDT remains committed to its research and innovation strategy which is highlighted now by our work on the COVID-19 project’s unique delivery format. RDT provides scale-up testing and bench strength support for the McMaster research team in the race to provide an effective product that can be produced and delivered on a world-wide scale. A successful outcome of this project and its application with our QuickStrip™ delivery system will create exciting new opportunities for RDT.”

About Rapid Dose Therapeutics

Rapid Dose Therapeutics Corp. is a publicly-traded Canadian Life Sciences company providing innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry — including nutraceutical, pharmaceutical and cannabis industries. Within the cannabis sector, RDT also provides a turn-key Managed Strip Service Program enabling RDT’s QuickStrip™ proprietary cannabis delivery technology to be licensed to select operators in identified markets. RDT’s service-based annuity contracts drive recurring revenue and facilitate rapid expansion into emerging markets across multiple consumer segments. RDT is committed to continually create innovative solutions for humans, animals and plants.

For more information, visit: www.rapiddose.ca

For inquiries please contact:

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws.

Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues and the dismissal of the CTT lawsuit, express, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks.  Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Probe Metals Makes New Discovery Grading 8.0 g/t Au over 8.8 Metres on the Cadillac Break East Option Property, Val-d’Or East Project, Quebec

Highlights:

• New Gold Trend identified with multiple drill intercepts on the eastern part of the Cadillac Break East Option Property

• Significant drill intercepts grading up to 8.0 g/t Au over 8.8 metres, including 45.9 g/t Au over 1.0 metre, 2.7 g/t Au over 6.0 metres including 13.8 g/t Au over 1 metre and 9.2 g/t Au over 1.1 metres

• New 3D IP survey in progress to outline new targets.

TORONTO, July 21, 2020 (GLOBE NEWSWIRE) — Probe Metals Inc. (TSX-V: PRB) (OTCQB: PROBF) (“Probe” or the “Company”) is pleased to announce additional results from its regional drill program on the Val-d’Or East Cadillac Break East Option property (the “Property”) located near Val-d’Or, Quebec. The property is currently under option from O3 Mining Inc (“O3 Mining”).  Results from an additional twenty-one (21) exploration drill holes and one drill hole extension identified a new gold trend in the eastern part of the Property (see figure 1). New discoveries were made along a 4.5-kilometre long portion of the trend, which has seen limited drilling in the past.  Selected highlights of the drill results are presented in the table below.

Dr. David Palmer, President and Chief Executive Officer of Probe, states: “One of the most important aspects of these results isn’t just that we have a new discovery, but rather that we have a discovery along a new trend that appears to be hosting multiple gold zones.  Although still early in the exploration, it is these kind of systems that we are looking for, ones with the potential to have more regional significance.  We are now expanding our exploration program to encompass more of this trend with follow-up geophysics and drilling.”

Hole CBE-40 was deepened to follow up on lower-grade gold assays returned from the bottom of the initial drill hole. In the deeper drilling, quartz-carbonates-tourmaline veins with visible gold returning 8.0 g/t Au over 8.8 metres, were intersected between 295 to 303.8 metres down the hole. The zone in Hole CBE-40 appears to be along the same trend that hosts earlier reported mineralisation grading 4.2 g/t Au over 4.2 metres from hole CBE-53 (June 16, 2020), approximately 3.8 kilometres to the east.  Four other holes (CBE-64,67,70 and 73) intersected encouraging gold results grading up to 2.7 g/t Au over 6.0 metres including 13.8 g/t Au over 1.0 metre along the trend and warrant follow-up drilling.  The new discoveries remain open in all directions.

Discoveries are associated with new geophysical targets delineated by high-power induced polarization (IP) surveys on the property. A new 3D high power IP survey to cover part of the trend between hole CBE-40 and 53 is currently in progress. Results from this survey will be used to delineate more potential gold targets along the new trend.

Selected drill results from the Cadillac Break East drilling program

(1) All the new analytical results reported in this release and in this table, are presented in core length and uncut. True width is estimated between 65 to 95 % of core length.

Figure 1: Surface Map – Eastern part of the Cadillac Break East property
https://www.probemetals.com/site/assets/files/1481/cbe-drill-results-pr-figures-july2020.pdf

About the Cadillac Break East Option Property:
On November 28, 2016, Probe entered into an option agreement with Alexandria Minerals Corporation, now O3 Mining, whereby Probe may earn 60% interest in the Cadillac Break East Property by spending an aggregate of $5,000,000 on exploration expenditures over 4 years. Probe may earn an additional 10% (total of 70%) interest in the Property by completing a pre-feasibility study, incurring an additional $2,000,000 in exploration expenditure, and issuing 200,000 common shares to O3 Mining on completion of the 70% earn-in requirement. To-date, Probe has completed exploration activities representing expenditures of over $4.3 million on the Property. Owing to the closure of non-essential business from March 24 to May 11 by the Quebec Government, the winter drill program was interrupted. O3 Mining and Probe agreed to extend the expenditure obligation under the option agreement to April 28, 2021. Following the identification of a new gold-mineralized zone, Probe will continue the drilling program on the new gold zone during the 2020-2021 winter season. Probe is the operator of exploration programs on the Property.

The Property is relatively underexplored, and it is generally recognized that the geological environment shows potential for both gold and base metals. The Property is underlain by mafic to felsic volcanic rocks and related sills of the Malartic Group, underlying the north half of the property, in contact with sedimentary rocks of the Pontiac Group, to the south. The contact between the two geologic terrains is the Cadillac Break Deformation Zone, a major geologic fault zone that controls the location of many gold deposits over a distance of 300 kilometers in Quebec and Ontario.

Located along the north edge of the property is the Sleepy gold deposit, which hosts a Current Resource of 1,855,300 tonnes @ 5.1 g/t gold, for a total of 307,350 inferred ounces of gold, uncapped (see Alexandria Minerals Press Release, October 22, 2014). The gold resources occur as disseminated gold-pyrite mineralization hosted in the Vicour Sill, a differentiated, 7 kilometre long gabbro-diorite sill. Beyond the Sleepy area, exploration work since the 1920’s has consisted of primarily early stage exploration programs consisting of geophysical surveys and limited drilling.

Qualified Person:
The technical content of this press release has been reviewed by Mr. Marco Gagnon, P.Geo, who is a “Qualified Person” within the meaning of NI 43-101, and Executive Vice-President and a director of Probe.

Quality Control
During the last drilling program, assay samples were taken from the NQ core by sawing the drill core in half, with one-half sent to a certified commercial laboratory and the other half retained for future reference. A strict QA/QC program was applied to all samples, which includes insertion of mineralized standards and blank samples for each batch of 20 samples. The gold analyses were completed by fire-assays with an atomic absorption finish on 50 grams of materials. Repeats were carried out by fire-assay followed by gravimetric testing on each sample containing 3.0 g/t gold or more. Total gold analyses (Metallic Sieve) were carried out on the samples which presented a great variation of their gold contents or the presence of visible gold.

About Probe Metals:
Probe Metals Inc. is a leading Canadian gold exploration company focused on the acquisition, exploration and development of highly prospective gold properties. The Company is committed to discovering and developing high-quality gold projects, including its key asset the Val-d’Or East Gold Project, Quebec. The Company is well-funded and controls a strategic land package of approximately 1,000-square-kilometres of exploration ground within some of the most prolific gold belts in Quebec. The Company was formed as a result of the sale of Probe Mines Limited to Goldcorp Inc. in March 2015. Newmont Corporation currently owns approximately 12% of the Company.

On behalf of Probe Metals Inc.,

Dr. David Palmer,
President & Chief Executive Officer

For further information:

Please visit our website at www.probemetals.com or contact:

Seema Sindwani
Director of Investor Relations
info@probemetals.com
+1.416.777.9467

Forward-Looking Statements

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This News Release includes certain “forward-looking statements” which are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, the Company’s objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate First Nations and other indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company’s public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

The oral care/oral hygiene market is projected to reach USD 53.3 billion by 2025 from USD 45.8 billion in 2020, at a CAGR of 3.1%

Growing awareness of the importance of maintaining good oral hygiene, increasing number of dental clinics and hospitals with dental dispensaries are major drivers in the growth of the oral care/oral hygiene market in the forecast period.

New York, July 21, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Oral Care/ Hygiene Market by Product, Toothpaste, Breath Freshener, Rinse & Distribution Channel, Region – Global Forecast to 2025” – https://www.reportlinker.com/p04961844/?utm_source=GNW

The oral care/oral hygiene market is expected to grow at a CAGR of 3.1% in the forecast period.
The oral care/oral hygiene market is projected to reach USD 53.3 billion by 2025 from USD 45.8 billion in 2020, at a CAGR of 3.1%. Factors such as the rising prevalence of dental diseases, growing awareness about oral health, growing geriatric population associated with edentulism, and growing number of small/private dental clinics with dental dispensaries are expected to drive the growth of the oral care/oral hygiene market. However, high dependancy on retail/consumer stores serves as a major challenge for the industry.
• By Product, the toothpastes segment holds the highest market share during the forecast period.

Based on product, the oral care/oral hygiene market is segmented into toothpastes, toothbrushes & accessories, mouthwashes/rinses, denture products, dental accessories/ ancillaries, and dental prosthesis cleaning solutions.The toothpastes segment held the highest market share in 2019.

The high market share of this segment can be attributed to the high adoption of toothpastes for maintaining oral hygiene and prevention of dental caries.

Based on Distribution Channel, the online distribution segment is expected to register the highest CAGR during the forecast period.
Based on distribution channel, the oral care/oral hygiene market is segmented into consumer stores, retail pharmacies, online distribution, and dental dispensaries.The online distribution segment is projected to register the highest CAGR during the forecast period.

The significant growth in the e-commerce sector owing to the increasing number of internet users and advantages such as low costs, free deliveries, availability of multi-brand oral care products, and ease of purchasing and product comparison are key growth drivers for this segment.
• By Region, The Asia Pacific region holds the highest market share during the forecast period.

The Asia Pacific holds the highest market share during the forecast period (2020 to 2025). Rapidly developing healthcare industry in China & India, growth in aging population, rising incidence of dental diseases, growing awareness about oral hygiene, increasing investments by key market players, availability of low-cost labor, and the presence of a favorable regulatory environment are supporting the growth of the oral care/oral hygiene market in the Asia Pacific region.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–34%, Tier 2–38% and Tier 3–28%
• By Designation – C-level–26%, Director-level–35%, Others–39%
• By Region – North America–17%, Europe–39%, Asia Pacific–28%, Latin America- 8%, Middle East and Africa–8%

Key players in the oral care/oral hygiene market
The key players operating in the oral care/oral hygiene market include Colgate-Palmolive Company (US), The Procter & Gamble Company (US), GlaxoSmithKline PLC (UK), Unilever PLC (UK), Koninklijke Philips N.V. (Netherlands), Johnson & Johnson (US), GC Corporation (Japan), Ultradent Products Inc (US), 3M Company (US), Lion Corporation (Japan), Church & Dwight Co., Inc. (US), Sunstar Suisse S.A. (Switzerland), Perrigo Company plc (Ireland), Dabur India Ltd. (India), Orkla (Norway), Dentaid, Ltd (Spain), Henkel AG & Co. KGaA (Germany), LG Household and Health Care Ltd (South Korea), The Himalaya Drug Company (India) & Young Dental (US).

Research Coverage:
The report analyzes the oral care/oral hygiene market and aims at estimating the market size and future growth potential of this market based on various segments such as product, distribution channel, and region.The report also includes a product portfolio matrix of various oral care products available in the market.

The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global oral care/oral hygiene market. The report analyzes this market by product and distribution channel.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global oral care/oral hygiene market
• Market Development: Comprehensive information on the lucrative emerging markets by product and distribution channel
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global oral care/oral hygiene market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global oral care/oral hygiene market.

Lithium-Sulfur (Li-S) Battery Market To Reach USD 6,686.2 Million By 2028;Quince Market Insights

Global Lithium-Sulfur (Li-S) Battery Market is anticipated to grow with a CAGR of 29.6% in terms of value from 2021 to 2028.The key players leading in the market are Oxis Energy, Poly Plus, and Sion Power

The Global Lithium-Sulfur (Li-S) Battery Market was valued at USD 696.1 Million in 2019 and is anticipated to reach USD 6,686.2 Million by 2028, with a CAGR of 29.6% during the forecast period. The first Li-S battery was invented in 1960 and was patented by Herbert and Ulam in 1962. They used Lithium or various Lithium alloys as an anodic material and Sulfur(S) as a cathodic medium. After the advancement of technologies and the invention of various organic solvents such as Propylene Carbonate (PC), Dimethyl Sulfoxide (DMSO) and Dimethylformamide (DMF) propelled the market dynamics of Lithium-Sulfur battery market. Ether was applied in Li-S battery in 1980 which was used as a solvent for the electrolytes.

Request For a Sample Copy Of This Research Report @ https://www.quincemarketinsights.com/request-sample-60223  

Li-S batteries are mainly used in aviation, automotive, electronic device, and power& energy sector due to the growing demand for green energy with high energy density as compared to other battery types. Lithium-Sulfur (Li-S) batteries provide lightweight to end-use applications due to low and moderate atomic weight of Lithium (Li) and Sulfur (S) and due to this reason, Li-S battery is widely used in the aerospace industry. Besides this, superior performance along with lower manufacturing costs, abundant supply of material, ease of processing and reduced environmental footprint propelled the growth of the Lithium-Sulfur (Li-S) battery market. Ultra-high capacity Lithium-Sulfur (Li-S) battery has better performance and less environmental impact to that of current Lithium-ion batteries.

High theoretical and practical energy density achieved by combining a lithium-metal anode with a sulfur cathode is the driving factor for Lithium-Sulfur battery technology. In the other side, the extremely low electrical conductivity of the Sulfur cathode requires an extra mass for the conductive agent to exploit the entire active mass contribution to the capacity. Large volume expansion of the Sulfur cathode from S to Li2S and the large quantity of electrolyte required also challenge to be addressed.

Global Lithium-Sulfur (Li-S) Battery Market, by Power Capacity

Based on power capacity, global Lithium-Sulfur (Li-S) battery market segmented into 0-500mAh, 501-1000 mAh, above 1000 mAh. Among these, 0-500mAh segment power capacity is anticipated to capture the largest market share in the global market in 2020 and is anticipated to remain largest till the forecast period. The growing adaptation of electric vehicles, hybrid cars and also the demand from the electronic industry further anticipated to boost the segments demand.

Enquiry Before Buying This Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-60223  

Global Lithium-Sulfur (Li-S) Battery Market, by End User

Based on End User, global Lithium-Sulfur (Li-S) battery market is segmented into aerospace, automotive, electronic device, power & energy, and others. Out of which, automotive segment is accounted for the largest share of more than 55.0% of the global market in 2020. It also anticipated that, increasing adaptation from the aerospace end user segment further attribute the market.

Global Lithium-Sulfur (Li-S) Battery Market, by Region:

Based on region, global Lithium-Sulfur (Li-S) battery segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, Middle East, and Rest of World. North America and Asia Pacific region capture near about two third of the global Lithium-Sulfur (Li-S) battery in 2020. In North America, U.S. is the leading market which is mainly attributed to the growing automotive and aerospace end user segment. In Asia Pacific, the growing demand from electric vehicles mainly in China and Japan are the major factors that will anticipate to drive the Li-S battery market in the region.

Some major findings of the global Lithium-Sulfur (Li-S) battery report include:

• Major global market trend & forecasts analysis along with the country specific market analysis up to 27 countries
• In-depth global Lithium-Sulfur (Li-S) battery market analysis by power capacity, end users, and regions with analysis of trend-based insights and factors
• Major key market players operating in Lithium-Sulfur (Li-S) battery market that include are Oxis Energy, Poly Plus, and Sion Power
• Competitive benchmarking, product offering details, growth strategies adopted by the leading market players along with their major investments in last five years
• Micro, Macro analysis factor analysis across the regions along with the drivers, restrains, opportunities, challenges, guidelines and regulations that are prevailing in the Lithium-Sulfur (Li-S) battery market
• In depth Porter’s, value chain and Porters analysis of the market

Browse key industry insights spread across 111 pages with 57 market data tables and 28 figures & charts from the report, “Lithium-Sulfur (Li-S) Battery Market, By Power Capacity (0-500mAh, 501-1000 mAh, above 1000 mAh), By End User(Aerospace, Automotive, Electronic Device, Power & Energy, Others), , By Region (North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, Rest of the World) – Market Size & Forecasting (2017-2028)” in depth analysis along with the table of contents (ToC).

Buy Now Complete Report @ https://www.quincemarketinsights.com/insight/buy-now/lithium-sulfur-li-s-battery-market/single_user_license  

Browse Related Reports:

• Global Lithium-Ion Battery Market, by Battery Type (Li-NMC, LTO, LCO, LFP, NCA, LMO), by Battery Component (Electrolytic Solution, Cathode, Anode and Others), by End-Use Industry (Automotive, Consumer Electronics, Industrial, Medical and Others), by Region (North America, Eastern Europe, Western Europe, Asia Pacific, Middle East, Rest of the World) – Market Size & Forecasting (2016-2028)

https://www.quincemarketinsights.com/industry-analysis/global-lithium-ion-battery-market/5007

• Global UAV Battery Market, By UAV Type (MALE, HALE, Tactical, Small), By Battery Type (Fuel Cell, Lithium Ion, Lithium Polymer, Nickel Cadmium), By Region (North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, Rest of the World) – Market Size & Forecasting (2016-2025)

https://www.quincemarketinsights.com/industry-analysis/uav-battery-market/58487

• Global Automotive Battery Market, by Battery Type (Lead Acid, Nickel Metal Hydride, Lithium-Ion and Others), by Battery Technology (SLI, AGM, Deep Cycle, Wet Cell and Others), by Vehicle Type (Passenger, Commercial, Electric and Others), by Region (North America, Eastern Europe, Western Europe, Asia Pacific, Middle East, Rest of the World) – Market Size & Forecasting (2016-2028)

https://www.quincemarketinsights.com/industry-analysis/global-automotive-battery-market/4149

• Global Battery Components Market, By Component Type (Anode, Cathode, Electrolyte, and Others), By Battery Type (Primary and Secondary), and By Region (North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, and Rest of the World) – Market Size & Forecasting (2016-2028)

          https://www.quincemarketinsights.com/industry-analysis/global-battery-components-market/32419

About US

Quince Market Insights is a global market research and consulting company publishing syndicate studies as well as consulting assignments pertaining to markets that promise high growth opportunities in strategic future. We are dedicated team of analysts with strong base in technical expertise as well as thorough understanding of the market dynamics. Some of key areas expertise includes chemicals, advanced materials, construction, mining, food & agriculture, automotive, machines & equipment, and others. We analyze emerging trends in relatively nascent markets that promise high growth opportunities in future. We focus towards precision research practices that provide accurate market estimations and forecasts. This helps our clients to make proper estimations with regards to demand analysis, regional growth, major competitors, and dynamics of the market.

Locast now streaming local TV channels in Miami, Ft. Lauderdale and West Palm Beach, Florida

Nonprofit gives viewers their important local TV channels during hurricane season, COVID-19 updates, election coverage – for free – over internet

MIAMI, July 21, 2020 (GLOBE NEWSWIRE) — Locast, the nonprofit local broadcast TV streaming service, is now delivering dozens of local TV channels via the internet, for free, to those living in the Miami, Ft. Lauderdale and West Palm Beach TV markets in Florida. Locast provides a public service by giving access to important local news, hurricane and storm coverage, emergency information, election coverage, sports, and entertainment programming to internet-connected devices. Locast also offers English and Spanish-language channels, including a Spanish-language TV guide.

The announcement was made this week as residents in Miami-Dade, Broward and Palm Beach counties face rising coronavirus infection rates and as they prepare for summer storms. More than 6.8 million TV viewers living in the Miami-Ft. Lauderdale-West Palm Beach designated market areas (DMA) can now tune in their local TV news on their mobile devices to stay informed of local emergency alerts concerning further outbreaks or closures due to COVID-19. Local TV will also be popular for watching election coverage in Florida, an historical battleground state, as well as the start of professional football this fall.

“For the first time, Floridians located within the Miami and West Palm Beach DMAs will be able to watch their local TV stations on their phones, tablets, laptops or streaming media devices,” said Locast Founder and Chairman David Goodfriend. “Local TV news is critical for broadcasting alerts about hurricanes, elections and coronavirus-related restrictions, making Locast an important lifeline for South Florida residents and for those who can’t get local TV channels from an off-air antenna or cannot afford a pay-TV subscription.”

Goodfriend continued, “Especially when dealing with health, safety, or participation in our democracy through voting, Locast performs a critical public service by increasing access to local broadcasting. South Floridians can stay on top of local emergency information, coverage of the upcoming political conventions, and more – on the go, over the Internet – through Locast.  We have used our best efforts to make local broadcast more accessible to you.”

With Locast, viewers using internet-connected devices can watch, for free, their locally produced broadcast TV in high definition via the Locast app or at www.locast.org. Locast also offers multi-language support by giving Spanish-language access to the Locast app’s user-interface, log-in screens, and program guide.

Locast delivers more than 40 local TV channels in the Miami-Ft. Lauderdale DMA, including ABC 10, NBC 6, CBS 4, FOX 7, PBS, PBS Kids, Estrella TV, MOVIES!, The CW, CourtTV, Univision, Telemundo and more.  Counties served by the Miami/Ft. Lauderdale DMA include Broward, Miami-Dade and Monroe, including the Florida Keys.

West Palm Beach viewers will have access to 28 channels including ABC 25, NBC 5, CBS 12, FOX 29, PBS, and PBS Kids, Azteca America, Mystery, ION, Grit, Justice Network and more. Counties served within the West Palm Beach/Ft. Pierce DMA include Martin, St. Lucie, Okeechobee, Palm Beach North and South, and Indian River.

Complete local TV guides are available at www.locast.org.

Locast now delivers local TV channels via the internet into 21 U.S. TV markets containing more than 134 million viewers or 41% of the U.S. population. Locast has more than 1.4 million users.

Locast operates under the Copyright Act of 1976 that allows nonprofit translator services to rebroadcast local stations without receiving a copyright license from the broadcaster. The federal statute (17 U.S.C. 111(a)(5)) states that a nonprofit organization may retransmit a local broadcast signal and collect a fee to cover the cost of operations. Locast asks viewers to donate as little as $5 per month to help cover operating costs. The donation is voluntary and not required.

Locast is available for streaming at www.locast.org, app stores, on DISH Hopper/Wally receivers, select DIRECTV receivers, TiVo, and at streaming service providers Google Play, Apple TV, Android TV, Amazon, and ROKU.

For more information, visit www.locast.org. Follow Locast on Facebook and Twitter @LocastOrg.

About Locast
Locast.org was founded by Sports Fans Coalition NY (SFCNY), a New York-based nonprofit, fan-advocacy group formed in 2017. Locast launched in 2018 and is available in 21 DMAs. SFCNY is the first local chapter of Sports Fans Coalition, Inc., which led the successful campaign to end the FCC’s Sports Blackout Rule and continues to advocate for fans. As a nonprofit, Locast is supported by user donations and is available at www.locast.org.

Press contact:

Marc Lumpkin
Altitude Public Relations for Locast
303-378-2366